A5067535594- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- Extracellular vesicles in disease
- Cancer Immunotherapy and Biomarkers
- Liver Diseases and Immunity
- Cancer-related cognitive impairment studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Biomarkers in Disease Prognosis
- Cancer, Lipids, and Metabolism
- RNA Interference and Gene Delivery
- Gastric Cancer Management and Outcomes
- Electroconvulsive Therapy Studies
- Renal and related cancers
- Cardiac Health and Mental Health
- Colorectal Cancer Screening and Detection
- Chemotherapy-induced cardiotoxicity and mitigation
- Nutrition and Health in Aging
- Renal cell carcinoma treatment
- Takotsubo Cardiomyopathy and Associated Phenomena
- Cancer, Hypoxia, and Metabolism
- Colorectal and Anal Carcinomas
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
Université Libre de Bruxelles
2024
Institut Jules Bordet
2024
Novartis (Switzerland)
2023
Jazz Pharmaceuticals (United States)
2023
Pfizer (United Kingdom)
2023
Roche (Switzerland)
2023
Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC).To explore the value IIs mCRC patients treated with first-line chemotherapy plus Bev.One hundred eighty-two diagnosed first line Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate...
The identification of predictive factors for treatment pancreatic cancer (PC) is an unmet clinical need. In the present work, we analyzed blood-derived extracellular vesicles (EVs) from patients with advanced PC in order to find a molecular signature response therapy. We samples 21 PC, all receiving first-line gemcitabine + nab-paclitaxel. Isolated EVs have been analyzed, and results laboratory matched data investigate possible factors. EV concentration size were similar between responder...
Circulating tumor DNA predicts prognosis of mCRC patients receiving first-line bevacizumab based-chemotherapy
Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches. Recent trials favor LCRT due to improved local control. However, tumor distant recurrence remains concern, prompting exploration of Total Neoadjuvant Therapy (TNT) as comprehensive treatment strat-egy. Immune checkpoint inhibitors (ICIs)...
The efficacy and cost-effectivness of Multigene Panel Next-Generation Sequencing (NGS) in directing patients towards genomically matched therapies remains uncertain. This study investigated metastatic colorectal cancer (mCRC) who underwent NGS analysis on formalin-fixed paraffin-embedded tumor samples. Data from 179 were analyzed, revealing no mutations 39 (21.8%), one mutation 83 (46.4%), two or more 57 (31.8%). KRAS found 87 (48.6%), including G12C 5 (2.8%), PIK3CA 40 (22.4%), BRAF 26...
Takotsubo syndrome (TTS) is an uncommon cardiovascular condition also known as stress-induced cardiomyopathy or broken heart disease. The syndrome, characterized by acute non-coronary segmental ventricular dysfunction, commonly occurs a reaction to severe emotional physical stress and can cause significant problems. Several classes of chemotherapeutic agents that are be cardiotoxic have been shown associated with TTS in cancer patients. Describing case from chemotherapy and/or monoclonal...
According to Europe's Beating Cancer Plan, the number of cancer survivors is growing every year and now estimated at over 12 million in Europe. A main objective European Commission ensure that can enjoy a high quality life, underlining role digital technology eHealth apps tools achieve this.The this study development user-centered artificial intelligence system facilitate input integration patient-related biopsychosocial data improve posttreatment well-being, health outcomes examine...
Abstract Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colorectal cancer (mCRC), however to date no predictive factors of response have been identified. Results our previous analysis on patients enrolled randomized prospective phase III multicenter study (ITACa study) showed value Vascular Endothelial Growth Factor ( VEGF ) polymorphism + 936), 27-nucleotide variable number tandem repeat (VNTR) the endothelial nitric oxide synthase eNOS gene and 894...
Background and aims: Perioperative treatment is currently the gold standard approach in Europe for locally advanced gastric cancer (GC). Unfortunately, phenomenon of patients dropping out has been frequently observed. The primary aims this study were to verify if routine blood parameters, inflammatory response markers, sarcopenia, depletion adipose tissues associated with compliance neoadjuvant/perioperative chemotherapy. Methods design: Blood samples considered before first second cycles...
Université libre de Bruxelles (ULB), Hôpital Universitaire (HUB), Institut Jules Bordet, Brussels, Belgium Correspondence to Francesco Sclafani, MD, PhD, Department of Gastrointestinal Oncology, Rue Meylemeersch 90,1070 Belgium. E-mail: [email protected]
Immune checkpoint inhibitors and immune-related biomarkers are increasingly investigated in rectal cancer (RC). We retrospectively analysed PD-L1 expression diagnostic biopsy resection samples from RC patients treated at our centre between 2000 2020. immunostaining (22C3 clone) was evaluated according to tumour proportion (TPS), immune cell (ICS), the combined positive score (CPS). Eighty-three were included. At diagnosis, ≥1%/≥5% observed 15.4%/0%, 80.7%/37.4%, 69.2%/25.6% of based on TPS,...
The efficacy and cost-effectiveness of Multigene Panel Next-Generation Sequencing (NGS) in directing patients towards genomically matched therapies remain uncertain. This study investigated metastatic colorectal cancer (mCRC) who underwent NGS analysis on formalin-fixed paraffin-embedded tumor samples. Data from 179 were analyzed, revealing no mutations 39 (21.8%), one mutation 83 (46.4%), two or more 57 (31.8%). KRAS found 87 (48.6%), including G12C 5 (2.8%), PIK3CA 40 (22.4%), BRAF 26...
Abstract Background: Pancreatic cancer (PC) has a 5-year survival of 12% despite recent therapeutic advancements. There is desperate need to discover novel ways treating PC since large proportion patients do not benefit from therapy and experience significant toxicity. A major cause failure resistance due tumor heterogeneity. Nowadays, deeper understanding heterogeneity could be assisted by the use patients-derived organoids (PDOs). Furthermore, liquid biopsy may allow for investigation...
Abstract Background: Biliary tract cancers (BTCs) refer to invasive malignancies of the biliary tree. Lack specific symptoms in early-stages frequently leads late-stage diagnosis, reducing therapeutic options. Surgical resection remains only curative option for early-stage disease; instead, patients with advanced disease usually receive chemotherapy (cisplatin plus gemcitabine) combination durvalumab as first-line treatment and mFOLFOX-6 second-line, but effects are limited a small...
Abstract Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colorectal cancer (mCRC), however to date no predictive factors of response have been identified. Results our previous analysis on patients enrolled randomized prospective phase III multicenter study (ITACa study) showed value Vascular Endothelial Growth Factor ( VEGF ) polymorphism + 936), 27-nucleotide variable number tandem repeat (VNTR) the endothelial nitric oxide synthase eNOS gene and 894...
<sec> <title>BACKGROUND</title> According to Europe’s Beating Cancer Plan, the number of cancer survivors is growing every year and now estimated at over 12 million in Europe. A main objective European Commission ensure that can enjoy a high quality life, underlining role digital technology eHealth apps tools achieve this. </sec> <title>OBJECTIVE</title> The this study development user-centered artificial intelligence system facilitate input integration patient-related biopsychosocial data...